Latest Biodefense News

Page 2 of 2

Recce Pharmaceuticals Secures $15.8M Capital Raise Amid Phase 3 Trial Expansion

Recce Pharmaceuticals advances its clinical pipeline with expanded Phase 3 trials in Indonesia and Australia, backed by a $15.8 million capital raise and a $30 million debt facility.

Ada Torres

31 July 2025

Top